NasdaqGM - Delayed Quote USD

MediciNova, Inc. (MNOV)

Compare
1.8500 +0.0400 (+2.21%)
At close: October 16 at 4:00 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Dr. Yuichi Iwaki M.D., Ph.D. Co-Founder, President, CEO & Executive Director 907.26k -- 1950
Dr. Kazuko Matsuda M.D., M.P.H., Ph.D. Chief Medical Officer & Director 649.05k -- 1966
Mr. Jason J. Kruger CPA CFO & Principal Financial Officer -- -- 1978
Dr. David H. Crean M.B.A., Ph.D. Chief Business Officer -- -- 1965
Mr. John O'Neil CPA Controller -- -- --

MediciNova, Inc.

4275 Executive Square
Suite 300
La Jolla, CA 92037
United States
858 373 1500 https://www.medicinova.com
Sector:?
Healthcare
Industry:?
Biotechnology
Full Time Employees:?
13

Description

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.

Corporate Governance

MediciNova, Inc.’s ISS Governance QualityScore as of October 1, 2024 is 7. The pillar scores are Audit: 8; Board: 8; Shareholder Rights: 5; Compensation: 7.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

November 7, 2024 at 9:00 PM UTC - November 11, 2024 at 9:00 PM UTC

MediciNova, Inc. Earnings Date

Recent Events

August 8, 2024 at 12:00 AM UTC

10-Q: Periodic Financial Reports

June 12, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

May 9, 2024 at 12:00 AM UTC

10-Q: Periodic Financial Reports

April 26, 2024 at 12:00 AM UTC

DEFA14A: Proxy Statements

April 1, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

February 15, 2024 at 12:00 AM UTC

10-K: Periodic Financial Reports

January 19, 2024 at 12:00 AM UTC

S-8 POS: Offering Registrations

November 9, 2023 at 12:00 AM UTC

10-Q: Periodic Financial Reports

August 9, 2023 at 12:00 AM UTC

10-Q: Periodic Financial Reports

August 7, 2023 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

Related Tickers